Are Loxo Shareholders Getting Enough in the Buyout?

By Chris Lange Updated Jan 31, 2:26AM EST · Published Jan 7, 11:05AM EST

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Are Loxo Shareholders Getting Enough in the Buyout? — © xrrr / iStock

Loxo Oncology Inc. (NASDAQ: LOXO) shares made a massive gain on Monday after it was announced that the firm would be acquired by Eli Lilly and Co. (NYSE: LLY | LLY Price Prediction). The transaction is not subject to any financing conditions and is expected to close by the end of the first quarter of 2019.

Under the terms of the deal, Eli Lilly to acquire Loxo Oncology for $235 per share in cash, or roughly $8.0 billion in total. This transaction represents a premium of 58% from the 50-day moving average of $148.38.

Note that this acquisition would be the largest and latest in a series of transactions Eli Lilly has conducted to broaden its cancer treatment efforts with externally sourced opportunities for first-in-class and best-in-class therapies.

For some quick background: Loxo Oncology is developing a pipeline of targeted medicines focused on cancers that are uniquely dependent on single gene abnormalities that can be detected by genomic testing. For patients with cancers that harbor these genomic alterations, a targeted medicine could have the potential to treat the cancer with dramatic effect.

[nativounit]

Anne White, president of Lilly Oncology, commented:

The acquisition of Loxo Oncology represents an exciting and immediate opportunity to expand the breadth of our portfolio into precision medicines and target cancers that are caused by specific gene abnormalities. The ability to target tumor dependencies in these populations is a key part of our Lilly Oncology strategy. We look forward to continuing to advance the pioneering scientific innovation begun by Loxo Oncology.

Shares of Loxo were last seen up about 66% at $232.07, in a 52-week range of $82.74 to $233.76. The stock has a consensus analyst price target of $203.40.

Eli Lilly was down 1% at $113.50 a share, with a consensus price target of $117.88. The 52-week trading range is $73.69 to $119.84.

[recirclink id=519562]

[wallst_email_signup]

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.